Previous Page  26 / 30 Next Page
Information
Show Menu
Previous Page 26 / 30 Next Page
Page Background

Page 66

Notes:

Journal of Clinical & Experimental Pathology | ISSN: 2161-0681 | Volume 8

December 03-04, 2018 | Chicago, USA

American Pathology and Oncology Research

&

15

th

International Congress on

Microbial Genetics and Molecular Microbiology

International Conference on

Delving KS-01 as a novel therapeutic strategy in treating breast cancer

Sourav Taru Saha

and

Mandeep Kaur

University of the Witwatersrand, South Africa

C

ancer cells have an increased need for cholesterol, which is required for cell membrane integrity. Cholesterol accumulation has

been described in various malignancies including breast cancer. Cholesterol has also been known to be the precursor of estrogen

and vitamin D, both of which play a key role in the histology of breast cancer. Thus, depleting the cholesterol levels in cancer cells is

a proposed innovative strategy to treat cancer. Therefore, novel cholesterol-depleting compounds are currently being investigated.

KS-01 is a cyclic amylose oligomer composed of glucose units. It solubilizes the cholesterol and is proven to be toxicologically benign

in humans. This led us to hypothesize that it might deplete cholesterol from cancer cells and may prove to be a clinically useful

compound. Our work provides preliminary experimental evidences to support this hypothesis. We identified the potency of KS-01

in vitro against two breast cancer cell lines: MCF-7 (Estrogen positive, ER+), MDA-MB-231 (Estrogen negative, ER-) and compared

the results against two normal cell lines: MRC-5 (Normal Human Lung Fibroblasts) and HEK-293 (Normal human embryonic

kidney cells) using cytotoxic, apoptosis and cholesterol based assays. KS-01 treatment reduced intracellular cholesterol resulting in

significant breast cancer cell growth inhibition through apoptosis. The results hold true for both ER+ and ER-. These data suggest that

KS-01 can prevent cholesterol accumulation in breast cancer cells and is a promising new anticancer agent.

1575707@students.wits.ac.za

J Clin Exp Pathol 2018, Volume 8

DOI: 10.4172/2161-0681-C5-058